First AD

Second AD

Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.

Women’s use of facial skin care products saw a significant rise in 2020 due to the COVID-19 pandemic, according to The NPD Group, a market research company.

Exum Instruments, Inc. introduced Massbox, the first commercial instrument combining laser ablation and laser ionization under vacuum.

Lightigo exhibited FireFly, an instrument specializing on chemical imaging of solid samples and featuring a motorized objective turret, laser microfocus, and long depth of field. Lightigo’s FireFly could have also been placed in the “Imaging” category.

Agilent Technologies featured a helium mode collision cell and half mass correction to control polyatomic and doubly charged ion interferences.

It’s no secret that veterinary professionals are resilient. During the COVID-19 pandemic, the profession was confronted with significant challenges but adjusted to sudden, drastic changes and propelled forward to meet the new and growing demands.

 and if our profession is resilient, that means the professionals within the profession are resilient,” said Kara Burns, MS, MEd, LVT, VTS (Nutrition). “If we’re resilient it means we [have] recovered from [things] and learned to change course and move forward.”

When faced with adversity because of a worldwide pandemic or a challenging situation in the clinic—having the right tools to help you maintain resiliency is crucial. During her talk during the 2021 vi

-6482) showed that with further follow-up, the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau (VHL)–associated renal cell carcinoma (RCC) treated in the frontline setting. U

 sat down with Pedro Machado, MD, PhD, to discuss his EULAR 2021 presentation entitled,
“COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease.”